Prevalence and effect of occult hepatitis C infection in patients with persistent liver enzyme elevation after achieving 24 weeks of sustained virological response

Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol 2015; 7: 2100–2109.

Bartolome J, Castillo I, Quiroga JA, Carreno V. Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection. J Med Virol 2016; 88: 268–274.

Austria A, Wu GY. Occult hepatitis C virus infection: a review. J Clin Transl Hepatol 2018; 28: 155–160.

Welsch C, Efinger M, von Wagner M, Herrmann E, Zeuzem S, Welzel TM, Lange CM. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. PLoS One 2017; 12:e0171755.

Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013; 158: 114–123.

Lin H, Chen X, Zhu S, Mao P, Zhu S, Liu Y et al. Prevalence of occult hepatitis C virus infection among blood donors in Jiangsu, China. Intervirology 2016; 59: 204–210.

Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernández N et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19: 2288–2292.

Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJIII. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008; 47: 880–887.

Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, Kottilil S. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis 2015; 15: 1743–1751.

Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F et al. Association between sustained virological and advanced hepatic fibrosis. JAMA 2012; 308:2584–2593.

Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675–683.

Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006; 13: 73–80.

Castèra L, Hézode C, Roudot-Toraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288–292.

Schlevogt B, Deterding K, Port K, Siederdissen CHZ, Sollik L, Kirschner J et al. Interferon-free cure of chronic hepatitis C is associated with weight gain during long-term follow-up. Z Gastroenterol 2017; 55: 848–856.

Elmasry S, Wadhwa S, Bang B-R, Cook L, Chopra S, Kanel G et al. Detection of occult hepatitis C virus infection in patients who achieved a sustained virological response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology 2017; 152: 550–553.